Fulcrum Therapeutics Inc.

4.08
0.08 (2.00%)
Jan 22, 2025, 3:46 PM - Market open
2.00%
Bid n/a
Market Cap 220.34M
Revenue (ttm) 69.89M
Net Income (ttm) -15.48M
EPS (ttm) -0.29
PE Ratio (ttm) -14.09
Forward PE -2.98
Analyst Hold
Ask n/a
Volume 287,818
Avg. Volume (20D) 901,675
Open 3.93
Previous Close 4.00
Day's Range 3.93 - 4.14
52-Week Range 2.86 - 13.70
Beta 2.23

About FULC

Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy; and FTX-6058, an investigational oral fetal hemoglobin inducer for the treatment of sickle cell di...

Industry Biotechnology
Sector Healthcare
IPO Date Jul 18, 2019
Employees 76
Stock Exchange NASDAQ
Ticker Symbol FULC

Analyst Forecast

According to 9 analyst ratings, the average rating for FULC stock is "Hold." The 12-month stock price forecast is $4, which is a decrease of -2.08% from the latest price.

Buy 33.33%
Hold 55.56%
Sell 11.11%
Stock Forecasts
3 months ago
+15.27%
Fulcrum Therapeutics shares are trading higher aft... Unlock content with Pro Subscription
4 months ago
-7.56%
Fulcrum Therapeutics shares are trading lower after HC Wainwright & Co and RBC Capital downgraded the company and lowered their respective price targets on the stock.